Aller au contenu principal
Accès ouvert déclaré 2024 article

On-Treatment Change in d -Dimer Is Associated With Differential Outcomes Among Therapeutic Dose Heparin-Treated Noncritically Ill Patients Hospitalized for COVID-19

1Citations signalées, ce qui n’est pas une note de qualité
17Institutions déclarées
3Pays d’affiliation déclarés

Rattachement africain : us, ca, au. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

This study is reporting on a clinical randomized control trial: Yes Clinical trial reports should comply with the Consolidated Standards of Reporting Trials ( CONSORT) including its additional extensions as appropriate.This should include a flow diagram presenting the screening, enrollment, intervention allocation, follow-up, and data analysis with number of subjects for each.Please refer specifically to the CONSORT Checklist of items to include when reporting a randomized clinical trial and provide the completed checklist at the time of submission.Please confirm and provide the following details at this time: Clinical Trial RegistrationClinical trials should be registered in an appropriate online trial registry at or before the onset of participant enrollment.In the box below, please provide the name of the trial registry, the registry URL, and the trial registration number.If your study is a clinical trial but not registered, please provide an explanation below.https://classic.clinicaltrials.gov/ct2/show/NCT04505774 Sex and Race/Ethnicity Specific ResultsSex and race/ethnicity specific results of the trial's primary outcomes are reported regardless of whether there are significant differences by sex or race. Yes Diverse Representation -ParticipantsWere steps taken to ensure diverse representation among trial participants, and if so, are these efforts outlined in the methods?If No, a lack of diversity should be explained and listed as a limitation. Yes Diverse Representation -Steering CommitteeWere steps taken to ensure diverse representation among the trial steering committee, and if so, are these efforts outlined in the Methods including demographic information?If No, a lack of diversity should be explained and listed as a limitation.Yes

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref
On-Treatment Change in <scp>d</scp> -Dimer Is Associated With Differential Outcomes Among Therapeutic Dose Heparin-Treated Noncritically Ill Patients Hospitalized for COVID-19
Date Crossref
01/01/2025
Éditeur
Ovid Technologies (Wolters Kluwer Health)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

COVID-19 Clinical Research StudiesVenous Thromboembolism Diagnosis and ManagementHeparin-Induced Thrombocytopenia and Thrombosis

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.